ReviewCureus2025
Overcoming the Blood-Brain Barrier: Focused Ultrasound in Glioblastoma Treatment.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Meningeal immunity and "Interstitial" therapy: a new paradigm for immunotherapy in glioblastoma.Frontiers in immunology · 2026Review
- Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent advancements in neuro-oncology, glioblastoma remains one of the cancers with the poorest prognosis. Tumor recurrence and progression are driven by tumor stem cells and a high mutational burden. New potential treatment modalities are actively being explored. One promising approach is focused ultrasound (FUS), which involves converging ultrasound waves on a specific region of interest while avoiding damage to surrounding tissue. This mini-review highlights the current understanding of glioblastoma treatment resistance and positions FUS as a promising therapeutic option. We discuss existing clinical research utilizing FUS in four key treatment applications: (1) blood-brain barrier disruption, (2) histotripsy, (3) thermal ablation, and (4) sonodynamic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.